Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C

References

• Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis 2013;57(Suppl 2):S56-61
   Google Scholar
• Zaltron S, Spinetti A, Biasi L, et al. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis 2012;12(Suppl 2):S2
   Google Scholar
• Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 2011;171(3):242-8
   PubMedGoogle Scholar
• Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013;368(20):1859-61
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 2005;11(Suppl 10):S286-95. quiz S307-211
   Google Scholar
• Roberts HW, Utuama OA, Klevens M, et al. The contribution of viral hepatitis to the burden of chronic liver disease in the United States. Am J Gastroenterol 2014;109(3):387-393. quiz 386, 394
   PubMed Web of Science ®Google Scholar
• Tsui JI, Maselli J, Gonzales R. Sociodemographic trends in national ambulatory care visits for hepatitis C virus infection. Dig Dis Sci 2009;54(12):2694-8
   Google Scholar
• Loria P, Lonardo A, Anania F. Liver and diabetes. a vicious circle. Hepatol Res 2013;43(1):51-64
   PubMed Web of Science ®Google Scholar
• Peres DP, Cheinquer H, Wolf FH, et al. Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients. Ann Hepatol 2013;12(6):871-5
   Google Scholar
• Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000;133(8):592-9
   PubMedGoogle Scholar
• Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003;38(1):50-6
   PubMed Web of Science ®Google Scholar
• Deltenre P, Louvet A, Lemoine M, et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011;55(6):1187-94
   Google Scholar
• Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011;34(3):297-305
   PubMed Web of Science ®Google Scholar
• Konishi I, Horiike N, Hiasa Y, et al. Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Hepatol Res 2007;37(5):331-6
   Google Scholar
• Guiltinan AM, Kaidarova Z, Custer B, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008;167(6):743-50
   PubMed Web of Science ®Google Scholar
• Laryea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007;13(8):1109-14
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Nader F, et al. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther 2013;37(6):647-52
   PubMed Web of Science ®Google Scholar
• Petta S, Macaluso FS, Craxi A. Cardiovascular diseases and HCV infection: a simple association or more? Gut 2014;63(3):369-75
   PubMed Web of Science ®Google Scholar
• He H, Kang R, Zhao Z. Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis. PLoS One 2013;8(11):e81305
   PubMed Web of Science ®Google Scholar
• Simo R, Lecube A, Genesca J, et al. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006;29(11):2462-6
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008;48(5):721-7
   PubMed Web of Science ®Google Scholar
• Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49(3):739-44
   PubMed Web of Science ®Google Scholar
• Huang JF, Dai CY, Yu ML, et al. Pegylated interferon plus ribavirin therapy improves pancreatic beta-cell function in chronic hepatitis C patients. Liver Int 2011;31(8):1155-62
   Google Scholar
• Aghemo A, Prati GM, Rumi MG, et al. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology 2012;56(5):1681-7
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007;102(3):570-6
   PubMed Web of Science ®Google Scholar
• Chehadeh W, Al-Nakib W. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy. J Med Virol 2009;81(4):610-18
   Google Scholar
• Chehadeh W, Abdella N, Ben-Nakhi A, et al. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol 2009;24(1):42-8
   PubMed Web of Science ®Google Scholar
• Zhang W, Rao HY, Feng B, et al. Effects of interferon-alpha treatment on the incidence of hyperglycemia in chronic hepatitis C patients: a systematic review and meta-analysis. PLoS One 2012;7(6):e39272
   PubMed Web of Science ®Google Scholar
• Serfaty L, Forns X, Goeser T, et al. Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 2012;61(10):1473-80
   PubMed Web of Science ®Google Scholar
• Hsu CS, Kao JH, Chao YC, et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther 2013;38(4):415-23
   PubMed Web of Science ®Google Scholar
• Maryland Department of Health and Mental Hygiene. Health Data: Cancer and Chronic Disease. Available from: http://dhmh.maryland.gov/data/SitePages/Chronic%20Diseases.aspx. [Last accessed 6 December 2013]
   Google Scholar
• Long SK, Coughlin TA, Kendall SJ. Access to care among disabled adults on Medicaid. Health Care Financ Rev 2002;23(4):159-73
   PubMedGoogle Scholar
• Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007;46(1):37-47
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Gutterman EM, Hodes D, Klaskala W. Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C. J Viral Hepat 2005;12(2):176-85
   PubMed Web of Science ®Google Scholar
• Happe LE, Lunacsek OE, Kruzikas DT, Marshall GS. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. Pediatr Infect Dis J 2009;28(2):98-101
   PubMed Web of Science ®Google Scholar
• Menzin J, White LA, Nichols C, Deniz B. The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective. BMC Health Serv Res 2012;12:459
   PubMed Web of Science ®Google Scholar
• Kim YA, Nguyen MH, RIchards KM, et al. Poor adherence to HCV therapy in a Medicaid population Poster. In: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. Montreal, Canada;2014
   Google Scholar
• McAdam-Marx C, McGarry LJ, Hane CA, et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manage Care Pharm 2011;17(7):531-46
   PubMed Web of Science ®Google Scholar
• Chang HY, Weiner JP, Richards TM, et al. Predicting costs with diabetes complications severity index in claims data. Am J Manage Care 2012;18(4):213-19
   Google Scholar
• Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39(4):1147-71
   PubMed Web of Science ®Google Scholar
• Missiha S, Heathcote J, Arenovich T, Khan K. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007;102(10):2181-8
   Google Scholar
• McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000;119(5):1317-23
   PubMed Web of Science ®Google Scholar
• Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010;33(3):562-8
   PubMed Web of Science ®Google Scholar
• Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010;55(13):1310-17
   PubMed Web of Science ®Google Scholar
• Aponte J. Prevalence of normoglycemic, prediabetic and diabetic A1c levels. World J Diabetes 2013;4(6):349-57
   Google Scholar
• Anselmino M, Sillano D. Impact of pre-diabetes and diabetes on cardiovascular outcomes. Curr Vasc Pharmacol 2012;10(6):680-3
   Google Scholar
• Wei LJ, Glidden DV. An overview of statistical methods for multiple failure time data in clinical trials. Stat Med 1997;16(8):833-9. discussion 841-851
   PubMed Web of Science ®Google Scholar
• Guo Z, Gill TM, Allore HG. Modeling repeated time-to-event health conditions with discontinuous risk intervals. An example of a longitudinal study of functional disability among older persons. Methods Inf Med 2008;47(2):107-16
   Web of Science ®Google Scholar
• Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007;132(1):103-12
   Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-74
   PubMed Web of Science ®Google Scholar
• Raza A, Mittal S, Sood GK. Interferon-associated retinopathy during the treatment of chronic hepatitis C: a systematic review. J Viral Hepat 2013;20(9):593-9
   PubMed Web of Science ®Google Scholar
• Karbasi-Afshar R. Treatment of hepatitis C virus infection and associated vascular complications: a literature review. Iran J Med Sci 2014;39(3):238-46
   Google Scholar
• Zhao W, Ji F, Yu S, et al. Dilated cardiomyopathy and hypothyroidism associated with pegylated interferon and ribavirin treatment for chronic hepatitis C: case report and literature review. Braz J Infect Dis 2014;18(1):110-13
   Google Scholar
• Katz LH, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients. Cochrane Database Syst Rev 2012;9:CD008516
   Google Scholar
• Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007;46(6):1688-94
   Google Scholar
• Keeffe EB. Chronic hepatitis C: management of treatment failures. Clin Gastroenterol Hepatol 2005;3(10 Suppl 2):S102-5
   Google Scholar
• Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis 2006;42(1):82-91
   Google Scholar
• Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 2011;106(1):38-45
   Google Scholar
• Wojcik G, Latanich R, Mosbruger T, et al. Variants in HAVCR1 gene region contribute to hepatitis C persistence in African Americans. J Infect Dis 2014;209(3):355-9
   Google Scholar
• Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131(2):470-7
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC Health Disparities & Inequalities Report. In: Morbidity and Mortality Weekly Report. United States: 2011. p. 1-116
   Google Scholar
• Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010;30(2):240-50
   Google Scholar
• Mitra D, Davis KL, Beam C, et al. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Value Health 2010;13(4):479-86
   Google Scholar
• Negro F. Hepatitis C in 2013: HCV causes systemic disorders that can be cured. Nat Rev Gastroenterol Hepatol 2014;11(2):77-8
   Google Scholar
• Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011;52(7):889-900
   PubMed Web of Science ®Google Scholar
• Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158(5 Pt 1):329-37
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308(24):2584-93
   PubMed Web of Science ®Google Scholar
• Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010;8:29
   PubMed Web of Science ®Google Scholar
• Lee LY, Tong CY, Wong T, Wilkinson M. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int J Clin Pract 2012;66(4):342-55
   PubMed Web of Science ®Google Scholar